One group designed a novel dendrimer conjugated to the mTOR inhibitor rapamycin to successfully inhibit mTOR signalling and VEGF expression in prostate cancer cells and fibroblasts, and reduce fibroblast-mediated prostate tumour progression and metastasis.92 Another group targeted neuregulin (NRG1), which is highly expressed in the cancer cells and CAFs of PDAC. Here, MTOR is linked to Familial prostate cancer.